Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001628280-24-045965
Filing Date
2024-11-07
Accepted
2024-11-07 07:04:17
Documents
73
Period of Report
2024-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q avtx-20240930.htm   iXBRL 10-Q 1188129
2 EX-10.4 ex-104nonxemplyoeedirector.htm EX-10.4 21204
3 EX-31.1 ex-3113q2024.htm EX-31.1 10539
4 EX-31.2 ex-3123q2024.htm EX-31.2 10325
5 EX-32.1 ex-3213q2024.htm EX-32.1 11107
11 GRAPHIC avtx-20240930_g1.jpg GRAPHIC 215961
  Complete submission text file 0001628280-24-045965.txt   8088533

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT avtx-20240930.xsd EX-101.SCH 61868
7 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT avtx-20240930_cal.xml EX-101.CAL 71031
8 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT avtx-20240930_def.xml EX-101.DEF 405658
9 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT avtx-20240930_lab.xml EX-101.LAB 656783
10 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT avtx-20240930_pre.xml EX-101.PRE 531583
76 EXTRACTED XBRL INSTANCE DOCUMENT avtx-20240930_htm.xml XML 927052
Mailing Address 540 GAITHER ROAD SUITE 400 ROCKVILLE MD 20850
Business Address 540 GAITHER ROAD SUITE 400 ROCKVILLE MD 20850 410-522-8707
Avalo Therapeutics, Inc. (Filer) CIK: 0001534120 (see all company filings)

EIN.: 450705648 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-37590 | Film No.: 241433084
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)